Conditions: Advanced Non-small Cell Lung Cancer (NSCLC)
Keywords: NSCLC
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 90
Healthy volunteers: no

Brief summary:
This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study.

The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects with advanced non-small cell lung cancer who failed the first treatment.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: CS-7017 intervention 2: erlotinib
Intervention descriptions: intervention 1: CS-7017, Two 0.25mg Tablets administered twice daily intervention 2: Erlotinib; One 150mg tablet administered once daily

Protocol document: